INVESTOR RESOURCES
iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS
Corporate Overview
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions. They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure. The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost. The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.
iCHOR at LSI '24
Medline Review Articles
The Latest News
Dr Muck Provides Video Overview of iCHOR's iSWEEP
by iCHOR in News In this new video, Dr. Patrick Muck, Chief of Vascular Surgery; Program Director Vascular Fellowship & Integrated Residency at Good Samaritan Hospital in Cincinnati, shares his firsthand experience with iCHOR Vascular’s iSWEEP thrombectomy treatment system. Dr Muck begins with an interesting back-story on Dr. Thomas Fogarty’s development of the surgical Fogarty balloon methodology at Good Samaritan Hospital sixty…
Real-World Limited Market Release Evidence iCHOR 14F iDVT Venous Reperfusion System
The iCHOR iDVT venous reperfusion system has demonstrated consistent safety, efficacy, and procedural performance across a diverse spectrum of clinical presentations in limited market release evaluation accessing patients in both Hospital and Ambulatory settings. Clinical Evidence at a Glance In 77 documented procedures performed by 20 physicians, the iDVT platform achieved: 95% technical success rate and 93.5% procedural success rate…